There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chronic bone disease affecting millions of people worldwide. We have developed a combinatorial strategy for engineering bispecific inhibitors that simultaneously target the unique combination of c-FMS and α v β 3 integrin, which act in concert to facilitate bone resorption by osteoclasts. Using functional fluorescence-activated cell sorting (FACS)-based screening assays of random mutagenesis macrophage colony-stimulating factor (M-CSF) libraries against c-FMS and α v β 3 integrin, we engineered dual-specific M-CSF mutants with high affinity to both receptors. These bispecific mutants act as functional antagonists of c-FMS and α v β 3 integrin activation and hence of osteoclast differentiation in vitro and osteoclast activity in vivo. This study thus introduces a versatile platform for the creation of new-generation therapeutics with high efficacy and specificity for osteoporosis and other bone diseases. It also provides new tools for studying molecular mechanisms and the cell signaling pathways that mediate osteoclast differentiation and function.
Author summary
Many bone diseases-including osteoporosis, in which the bones become brittle and fragile from loss of tissue-are characterized by excessive and uncontrolled bone resorption by bone-destroying cells known as osteoclasts. Therefore, controlled and specific inhibition of osteoclast activity is a desired outcome in treatments for bone diseases. Osteoclast differentiation and function are coordinated by cell surface receptors, including c-FMS and α v β 3 integrin, which cooperate with one another to drive signals that are essential for osteoclast functions. Here, we describe the engineering, characterization, and testing of novel proteins that can target and inhibit both c-FMS and α v β 3 integrin at the same time, thereby providing a way of controlling osteoclast function. The study represents the first a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
Osteoporosis, a chronic skeletal disorder common in both women and men beyond the age of 50 [1] , is the underlying cause of more than 8.9 million fractures annually worldwide, with the consequent high burden of social and economic costs [2] . The drugs initially used for the management of osteoporosis in women were based on estrogens, but long-term administration of these drugs is associated with increased risk of breast cancer, cardiovascular disease, and dementia [3] [4] [5] . To date, the most commonly prescribed drugs for osteoporosis are bisphosphonates, but these drugs, too, have nonspecific adverse side effects, such as gastrointestinal toxicity, renal toxicity, hypercalcemia, osteonecrosis of the jaw, and more [6] . A different therapeutic direction was recently opened with the Food and Drug Administration (FDA) approval of the receptor for activation of the nuclear factor-kappa B (NF-кB) ligand (RANKL) antibody, denosumab, but the clinical promise of this drug has been offset by reports of adverse side effects, such as hypocalcemia [7] and atypical hip fractures [8] . Thus, there is a pressing need for new efficient and highly specific drugs for the management of osteoporosis.
Central to the pathogenesis of osteoporosis is excessive bone resorption by osteoclasts [9] . These cells differentiate from cells of the monocyte/macrophage lineage upon stimulation of two essential factors, monocyte/macrophage colony-stimulating factor (M-CSF) and RANKL [10] . The importance of M-CSF and its receptor c-FMS in osteoclast function has been clearly illustrated in a study showing that both M-CSF-deficient and c-FMS-deficient mice suffer from retarded skeletal growth and osteopetrosis [11] . Another factor that is essential for osteoclast functioning is α v β 3 integrin, as indicated, for example, in studies showing increased bone mass in integrin β 3 knockout mice due to a functional defect in their osteoclasts [12] [13] [14] [15] . The interaction of α v β 3 integrin with the bone matrix induces a cytoskeleton organization that polarizes the osteoclast's resorptive machinery to the bone/cell interface, where it creates an isolated compartment consisting of an actin ring surrounding a ruffled border essential for resorption by the matured osteoclasts.
Importantly, in addition to the distinctive roles of c-FMS and α v β 3 integrin in osteoclast activity, these two factors also play a cooperative role in bone resorption. M-CSF signaling regulates bone resorption by crosstalk through its receptor c-FMS, with the signaling being activated by α v β 3 integrin. This signaling regulates cytoskeleton rearrangement, as both M-CSF and α v β 3 integrin stimulate the same c-Src-initiated signaling complex essential for regulation of the osteoclast cytoskeleton [16] [17] [18] . In addition, c-FMS alters the conformation of α v β 3 integrin from a low-affinity to a high-affinity state [19] , and it activates the Rho GTPase family member Rac (which is essential for osteoclast cytoskeleton organization) in an α v β 3 -integrindependent manner [16, 20] . Moreover, it has been demonstrated that β 3 -integrin-deficient mice have elevated concentrations of serum M-CSF and that impaired expression of differentiation markers of β 3 -integrin-deficient osteoclasts can be rescued by an increased concentration of M-CSF, suggesting a compensation mechanism between the actions of these receptors [16] . In addition, c-FMS and α v β 3 integrin colocalize to the osteoclast cytoskeleton, suggesting that the crosstalk between these receptors takes place at the same cellular sites. Indeed, it has been shown that an endogenic complex of c-FMS and α v β 3 integrin coprecipitates from differentiated osteoclasts [21] . Thus, the functional and spatial coupling of c-FMS and α v β 3 integrin in osteoclast differentiation and function, together with the osteoclast-exclusive presentation and crosstalk of these two receptors, suggests that an antagonist that could bind simultaneously to these two target receptors would serve as a highly specific and effective antiresorptive drug [19, 22] .
We thus aimed to exploit both the osteoclast's need for functional c-FMS and α v β 3 integrin and the specific expression of these two factors as a platform for developing a new generation of bispecific c-FMS/α v β 3 integrin antagonists for application in osteoporosis therapy and as tools to study osteoclast biology. In our rational design, two focused libraries were constructed, in each of which an Arginine-Glycine-Aspartic acid (RGD) sequence (a motif crucial for α v β 3 integrin ligand binding) flanked by random amino acids was introduced into the dimerization interface of the M-CSF ligand with the aim to change its activity from agonistic to antagonistic. This modification blocks the interactions between two M-CSF monomers and hence their subsequent homodimerization and activation of the M-CSF/c-FMS signal transduction cascade (Fig 1) . Our combinatorial strategy to further develop this unique antagonist involved the screening of the abovementioned focused libraries against α v β 3 integrin. Thereafter, functional FACS-based screening assays were applied to quantitatively select for M-CSF mutants with the highest expression, stabilities and affinities for both α v β 3 integrin and c-FMS. With this approach, we generated a number of unique dual-specific M-CSF mutants capable of binding to and antagonizing the biological activity of both c-FMS and α v β 3 integrin in vitro and in vivo.
Results

Testing the compatibility of the M-CSF/c-FMS system with the yeast surface display method
The M-CSF glycoprotein is secreted as a homodimer that, upon binding to two c-FMS receptors, induces c-FMS autophosphorylation followed by activation of downstream signaling pathways [23] . Our strategy for converting M-CSF from an agonist into an antagonist of the c-FMS receptor relied on impairing the ability of M-CSF to dimerize. To this end, we exploited the critical role of the cysteine in position 31 in the covalent dimerization of wild-type M-CSF (M-CSF WT ) [24] , namely, we generated a mutant M-CSF with impaired covalent dimerization capability (designated M-CSF C31S ) by replacing C31 with a serine residue (S1A Fig 
Engineering and selection of M-CSF harboring RGD motif proteins with high affinity for c-FMS and α v β 3 integrin
To construct a dual-specific M-CSF monomer that can bind both c-FMS and α v β 3 integrin, two libraries were created by replacing one of two loops on the M-CSF C31S scaffold with RGD, flanked by three random amino acids on each side, namely, by XXXRGDXXX, where X represents any random amino acid (designated M-CSF RGD ) (S1B and S1C Fig) . To identify and isolate M-CSF variants with high affinity for both c-FMS and α v β 3 integrin, we generated a YSD construct (S3 Fig) that allowed us to separate high-affinity clones from low-affinity clones by using flow cytometry. After confirming that M-CSF RGD libraries were well expressed on the surface of the yeast cell wall and that these libraries did indeed bind 100 nM soluble c-FMS and 500 nM α v β 3 integrin (S4 Fig), we merged the two libraries and regarded them as a single library that consisted of 1.1 × 10 7 variants. For affinity maturation, the M-CSF RGD library was sorted in a stepwise manner against α v β 3 integrin and c-FMS by using FACS (Fig 2 and S5  Fig) . To identify the specific variants that would bind both c-FMS and α v β 3 integrin, we tested individual clones for c-FMS and α v β 3 integrin binding and identified three unique clones with high affinity for both receptors (S6 Fig) . These M-CSF RGD variants were designated 4.22, 4.24 (both from sort four), and 5.6 (from sort five) (S1F Fig). Selective binding of these three variants to α v β 3 integrin and not to other integrins was confirmed by evaluating their binding to α v β 3 , α 4 β 7 , α iib β 3 and α 5 β 1 integrins (250 nM) (S6 Fig) . Since all three variants showed high specificity for α v β 3 integrin, they were regarded as good candidates for osteoclast-specific drug development, since osteoclasts express high levels of α v β 3 integrin as early as 48 h of differentiation [26] .
Production, purification, and characterization of bispecific M-CSF RGD variants and monospecific M-CSF controls
We produced the bispecific M-CSF RGD protein variants and their monospecific controls, M-CSF c-FMS (S1E Fig) and M-CSF αvβ3 (S1D Fig), with the aim to characterize these proteins in their soluble forms. The proteins were expressed in Pichia pastoris, glycans were removed, and the nonglycosylated proteins were purified by using affinity and size exclusion chromatography, giving the expected size of approximately 21 kDa (S7A and S7E Fig) . Circular dichroism (CD) spectra of the purified proteins showed similar curves, corresponding to a protein that consists mostly of α-helix motifs, which means that the RGD loops did not cause a significant change in the protein secondary structure (S7C Fig To determine the specificity of the three M-CSF RGD variants for α v β 3 integrin vis-à-vis the other integrins produced in the human body, SPR was used to evaluate the binding of M-CSF RGD variants (1 μM) to four different RGD-binding integrins (α 3 β 1 , α 4 β 7 , α 5 β 1 , and α v β 3 ). Consistent with our previous results, α v β 3 integrin bound the soluble M-CSF RGD proteins with high affinity (S10A (Fig 4) , since there is no steric clash between the native receptor c-FMS and α v β 3 integrin. In spatial terms, the ligand could thus serve as a bispecific agent for both receptors.
R28 of RGD is the only residue contacting the α v subunit. The rest of the loop is located closer to β 3 . Almost all the mutant residues lie on the β 3 surface, making contact with integrin residues but still exposed to the surroundings (S12 Fig) . This configuration creates a total interaction surface of 1,483 Å 2 between M-CSF RGD variant 4.22 and α v β 3 integrin. The differences in RGD orientation in comparison to the crystal structure of α v β 3 integrin in a complex with cyclic RGD (cRGD) [29] are shown in S13 Fig  5D and 5E ). These data show the correlation between inhibition of c-FMS by the M-CSF RGD proteins and the binding affinity of the variant proteins to c-FMS. It is well known that human M-CSF WT can bind mouse c-FMS, but the binding affinity is much lower than that for mouse M-CSF to mouse c-FMS [30] . Nonetheless, the M-CSF RGD variants significantly inhibited c-FMS phosphorylation and successfully competed with murine M-CSF in cells expressing murine c-FMS even though the M-CSF RGD variants were of human origin. This finding suggests that the M-CSF RGD variants should be highly effective as antagonists even in mouse cell models. The same experiment was performed for Akt activation with and without recombinant M-CSF. Akt activation has previously been shown to prolong cell survival in response to c-FMS and α v β 3 integrin activation [31] . As expected, our protein variants did not spontaneously activate Akt phosphorylation (S15B Fig) , and they significantly inhibited M-CSFinduced Akt phosphorylation ( Fig 5F) . The M-CSF RGD variants, M-CSF c-FMS , and M-CSF αvβ3 inhibited Akt phosphorylation, with the normalized phosphorylation levels being lower than the basal level of the negative control ( Fig 5G) .
M-CSF RGD variants inhibit induction of Akt and c-FMS phosphorylation
M-CSF RGD inhibits actin belt formation in mature osteoclasts
For a mature osteoclast to resorb bone properly, it must form a unique structure termed the "sealing zone"; this structure consists of an actin ring made from a dense actin mesh connected by adhesion complexes called podosomes. The formation of the actin ring involves several stages: at the beginning, podosomes are formed throughout the cell in a scattered manner; then groups of podosomes form small actin structures, known as belts, and upon osteoclast maturation, the belts move to the cell periphery, cluster, and form an actin ring. Podosomes contain high levels of α v β 3 integrin, which is essential for the formation on bones of proper actin rings with condensed podosome networks [32, 33] . As opposed to cells grown on bone, osteoclasts cultured on glass produce actin belts but are unable to form stable actin rings. However, the preceding stages of the podosome network are similar for cells grown on bone and on glass and are known to be regulated by α v β 3 integrin [34] . To test whether the inhibition of α v β 3 integrin by bispecific M-CSF RGD variants affects the organization of podosome networks, mouse BMMs cultured on glass were allowed to differentiate into mature osteoclasts to the point that multinucleated cells were formed and exhibited an actin belt structure. At this point, the inhibitors were added, and the cells were incubated for an additional 24 h before they were fixed and stained. Cells incubated only with M-CSF and RANKL without any inhibitor (i.e., positive control) formed a dense continuous actin belt structure. Addition of the monospecific M-CSF c-FMS did not drastically inhibit actin belt formation and abundance, and osteoclasts presenting dense continuous actin belts were observed ( Fig 6A and 6B) ; nevertheless, scattered podosomes presenting immature belts were more abundant than in the positive controls (Fig 6, lower panel) . Addition of either cRGD peptide, a well-established α v β 3 integrin inhibitor [35] , or the monospecific M-CSF αvβ3 decreased actin belts' distribution ( Fig 6B) . The actin belts in cells incubated with these inhibitors had wider and fainter actin stain, probably as a failure of the podosomes to form condensed structures as higher distribution of scattered podosomes was observed in these cells. The bispecific M-CSF RGD variant 5.6, which exhibited the lowest affinity to α v β 3 integrin, showed the same phenotype as cRGD and M-CSF αvβ3 . Strikingly, the bispecific M-CSF RGD variants 4.22 and 4.24 had the highest impact on actin belt formation and density. Dense actin structures and even scattered podosomes were hard to detect, and instead, the actin stain in osteoclasts cultured in the presence of these inhibitors had a diffusible appearance throughout the cell (Fig 6, S16 Fig) .
M-CSF RGD variants inhibit osteoclast differentiation in vitro
To assess the ability of the three bispecific M-CSF RGD variants and their monospecific controls, M-CSF c-FMS and M-CSF αvβ3 , to inhibit osteoclast differentiation, we monitored the effects of elevated concentrations of these proteins in cultures of differentiating BMMs or human peripheral blood CD14 + monocytes. The proteins were added together with recombinant RANKL and human (for CD14 + cells) or murine (for BMMs) M-CSF to initiate osteoclast differentiation. We note that as osteoclasts differentiate, the number of nuclei and the surface area increase as a result of cell fusion and cytoskeletal rearrangements, respectively. Strikingly, in cultures of differentiating BMMs and CD14 + cells, all three M-CSF RGD variants inhibited the nuclei number, surface area, total osteoclast number, and tartrate-resistant acid phosphatase (TRAP) absorbance, with inhibition being significant at a concentration as low as 50 nM (Fig 7 and Fig 8) . To further validate the ability of the M-CSF RGD variants to inhibit osteoclast differentiation, the mRNA expression levels of osteoclast-associated receptor (OSCAR) and NFATc1-two well-known osteoclast differentiation markers exhibiting increased expression during osteoclast differentiation-were evaluated [36, 37] . The three M-CSF RGD variants significantly inhibited OSCAR and NFATc1 expression while M-CSF αvβ3 had no inhibitory effect (Fig 7F and 7G) . In general, the ability of the M-CSF monospecific controls to inhibit osteoclast differentiation was inferior to that of the bispecific M-CSF RGD variants, particularly in the human CD14 + cell cultures. Since M-CSF signaling is known to regulate osteoclast survival, inhibition of M-CSF is expected to lead to a decrease in osteoclast survival. Indeed, a smaller number of cells was observed in osteoclasts cultured in the presence of the M-CSF RGD variants. In addition, an assay for cell death, based on propidium iodide (PI) permeability, in differentiating osteoclast cultures showed that the three M-CSF RGD inhibitors and the M-CSF c-FMS significantly increased cell death versus the small molecule GW2580 (a known inhibitor for c-FMS phosphorylation) used in the control assay. We note that M-CSF αvβ3 was unable to induce cell death, probably because of its inability to bind c-FMS (Fig 7H) . To rule out nonspecific toxic effects of the M-CSF RGD variants on cell proliferation and survival, we added these inhibitors to murine bone-marrow-derived mesenchymal stromal cells (BMSCs), whose physiological microenvironment is the same as that of BMMs. No changes in survival and proliferation capabilities of BMSCs cultured with elevated concentrations of the M-CSF RGD variants were observed (Fig 7I) . Taken together, these results show that all M-CSF RGD variants are highly efficient in inhibiting osteoclast differentiation and spreading even at a low concentration and have no apparent toxic effects on other primary bone-marrow-residing cells.
In vivo biodistribution of M-CSF RGD variant 5.6
To evaluate the biodistribution of M-CSF RGD , we chose variant 5.6 because yields of this purified protein were higher than those for purified variants 4.22 and 4.24. The protein was stained Ã p < 0.05, ÃÃ p < 0.01, ÃÃÃ p < 0.001. Source data and analysis can be found in S4 Data. BMM, bone-marrow-derived monocyte; BMSC, bone-marrow-derived mesenchymal stromal cell; M-CSF, with DyLight 680-NHS (N-hydroxysuccinimide) Ester, and 2 nmol of stained variant 5.6 or unconjugated dye were injected subcutaneously (s.c.) into wild-type (WT) C57BL6 mice. The mice were killed 1.5 h and 3 h after injection, their organs were removed, and the accumulation of variant 5.6 in the organs was compared to that in a control untreated mouse. Variant 5.6 accumulated in the kidneys and the bladder as part of the natural clearance and not in other organs, such as the heart, liver, and spleen (Fig 9A, right) . Importantly, examination of the epiphysis and diaphysis of a C57BL6 mouse femur (Fig 9A, left) showed that variant 5.6 did indeed reach the bones. The observed accumulation of the unconjugated dye in the liver but not in the kidneys or in the bones served to confirm the specificity of variant 5.6 for bone tissue.
M-CSF RGD variants 4.22 and 5.6 inhibit osteoclast activity in an animal model of osteoporosis
To determine whether variants 4.22 and 5.6 (which gave better production yields than 4.24) inhibit osteoclast activity in vivo, we used the well-established mouse model of ovariectomyinduced bone loss (OVX). Two weeks after the mice had undergone ovariectomy or a sham operation, they were injected s.c. twice a day for 3 d with phosphate-buffered saline (PBS), variant 4.22, or variant 5.6. After the last injection, blood was collected, and serum concentrations of the marker for bone resorption (osteoclast activity), the cross-linked carboxy-terminal telopeptide of type I collagen (CTX-I), were determined using ELISA. Two weeks after the operation, there was a significant increase in serum CTX-I levels in ovariectomized mice injected with PBS as compared to the sham-operated mice. Analysis of the CTX-I levels in mice injected with variants 4.22 and 5.6 showed a significant reduction compared to ovariectomized mice injected with vehicle. Strikingly, serum CTX-I levels of mice that were injected with variant 5.6 were reduced almost to the level of CTX-I serum levels of the sham-operated mice (Fig 9B) .
Discussion
A number of studies have demonstrated the crosstalk between biological processes mediated by c-FMS, α v β 3 integrin, and their ligands in the context of osteoclast differentiation, cytoskeleton organization, and bone resorption [14, 16, 19] . Since enhanced osteoclast function is an underlying cause of many bone-related disorders, with osteoclast differentiation and function being dependent on c-FMS and α v β 3 integrin, these two proteins constitute attractive targets for therapeutic intervention. However, since these two receptors regulate common pathways, combination therapy or high drug doses may be needed to fully block the differentiation and resorption processes, with resulting increases in potential side effects and in the cost of therapy. Dual-specific proteins that could bind to and inhibit both c-FMS and α v β 3 integrin would therefore have superior therapeutic potential, as such proteins would offer improved binding avidity and selectivity compared to monospecific protein therapeutics. Nevertheless, despite extensive efforts in the field, there are currently no clinically approved therapeutic agents that are specific for both c-FMS and α v β 3 integrin. The new approach described here, which entails engineering dual-specific therapeutic proteins, is the first to use a natural ligand as a scaffold for engineering high-affinity binding to two therapeutic targets and to apply the engineered bispecific ligands in preclinical studies of osteoporosis. We have shown in this study that M-CSF is an excellent scaffold for engineering bispecific ligands with affinity and specificity for both c-FMS and α v β 3 integrin. Many integrins recognize the RGD motif in extracellular matrix ligands, including fibronectin, vitronectin, fibrinogen, and osteopontin [38] . Since the RGD motif in natural ligands is typically found in flexible solventexposed loops, we mutated either loop 1 or loop 3, both of which are located in the dimerization interface of M-CSF WT and remain accessible in M-CSF RGD monomers [39] . Mutating either one of these loops with an RGD sequence flanked by three residues on each side allows M-CSF RGD to interact with α v β 3 integrin. This interaction does not disrupt the contact with the native c-FMS receptor, as the latter interacts with residues located on the opposite side of the M-CSF RGD ligand. Overall, the interaction area between M-CSF RGD variant 4.22 and α v β 3 integrin is relatively large and scattered, in accordance with the physiological integrin-ligand interaction [40] .
The M-CSF RGD variants 4.22, 4.24, and 5.6 had enhanced inhibitory capabilities compared to M-CSF c-FMS and M-CSF αvβ3 , thereby highlighting the effects of the dual functionality that we engineered into these proteins. The M-CSF RGD variants were shown to be better inhibitors Ten-weeks-old mice were ovariectomized, and starting 2 wk after the surgery, they were injected twice a day with PBS or M-CSF RGD variants 4.22 or 5.6 for 3 d. Thereafter, serum CTX-I levels were determined by ELISA. Data are means ± SEM.
Ã p < 0.05, ÃÃ p < 0.01, ÃÃÃ p < 0.001. Source data and its analysis can be found in S6 Data. CTX-I, carboxy-terminal telopeptide of type I collagen; ELISA, enzyme linked immunosorbent assay; M-CSF, macrophage colony-stimulating factor; OVX, ovariectomy-induced bone loss; PBS, phosphate-buffered saline; RGD, ArginineGlycine-Aspartic acid; s.c., subcutaneously; WT, wild type. Bispecific targeting of c-FMS and α v β 3 integrin for osteoporosis of osteoclast actin ring formation and osteoclast differentiation than M-CSF c-FMS and M-CSF αvβ3 .We showed by SPR and cell-surface-binding assays that the engineered dual-specific M-CSF proteins can bind both α v β 3 integrin and c-FMS receptors, leading to antagonism of immediate signaling events (c-FMS and Akt phosphorylation) and downstream biochemical events regulating osteoclast differentiation. Moreover, the presence of α v β 3 integrin and c-FMS on the surface of the cell enhances M-CSF RGD 's capability to bind it and lead to a stronger inhibition than the monospecific controls.
The three M-CSF RGD proteins, 5.6, 4.22, and 4.24, which differed in the amino acids flanking the RGD motif, also differed in their binding affinities for c-FMS and α v β 3 integrin. These variations in affinities were translated into differences in their biological activities. Variant 5.6 had the highest binding affinity to c-FMS and accordingly showed the highest binding and inhibition of c-FMS and Akt phosphorylation in murine pre-osteoclast cells and the lowest inhibitory effect on actin ring formation. However, variant 5.6 exhibited lower inhibition of murine osteoclast differentiation in vitro than variants 4.22 and 4.24. The latter two variants showed higher binding affinity to α v β 3 integrin and a drastic inhibition of actin ring formation, which may suggest that increased binding to integrin led to a more efficient inhibition of murine osteoclast differentiation in vitro. This notion is supported by our observation that inhibition of murine osteoclast differentiation was higher for M-CSF αvβ3 (the α v β 3 -integrinonly binder) than for variant 5.6. In contrast, variant 5.6 showed higher efficiency than M-CSF αvβ3 in inhibiting human osteoclast differentiation in vitro. Moreover, variant 5.6 showed better inhibition of bone resorption in vivo than variant 4.22, which suggests that higher affinity to c-FMS results in stronger inhibition of human osteoclast differentiation in vitro and promotes inhibition of osteoclast activity in mice in vivo. These results could be explained by the fact that variant 5.6 exhibits better thermal stability than variant 4.22, although we cannot rule out the possibility that other differences, such as differences in proteostability, might affect their activities in vivo.
The main goal of this study was to exploit the attributes of M-CSF to engineer a versatile platform for the development of a targeted osteoporosis therapy. By demonstrating that this natural ligand could be engineered to function as a scaffold with the ability to target two receptors at the same time, we showed that engineering of natural agonists to function as receptor antagonists could become an alternative strategy for generating therapeutics not only for osteoporosis but also for other important biomedical targets. We envision that protein variants generated from such efforts could promote the development of the next generation of therapeutics, including, but not limited to, targeted drug delivery agents and selective tissue targeting probes. Similarly, this approach will provide new tools for studying molecular mechanisms and cell signaling pathways-not only those that mediate osteoclast differentiation and function but also pathways that are involved in different pathological processes.
Methods
Ethics statement
This study was carried out according to protocols approved by the Ben-Gurion University Committee for the Ethical Care and Use of Animals in Experiments (permit number: IL32072017). All surgery was performed under anesthesia, and all efforts were made to minimize discomfort, distress, and suffering.
Flow cytometry sorting and analysis
For expressing the M-CSF C31S gene and the two M-CSF RGD libraries on the yeast surface, the yeast culture was grown in the tryptophan-selective SDCAA medium (2% dextrose, 0.67% yeast nitrogen base, 0.5% bacto casamino acids, 1.47% sodium citrate, 0.429% citric acid monohydrate, pH 4.5). This was followed by suspension in SGCAA medium (2% galactose, 0.67% yeast nitrogen base, 0.5% bacto casamino acids, 1.47% sodium citrate, 0.429% citric acid monohydrate) for overnight incubation at 30˚C until the culture reached OD 600 = 10.0 (10 8 cells per ml). A number of cells equal to 10 times the library size was added to 1 ml PBS containing 1% bovine serum albumin (PBSA); the suspension was centrifuged, and the supernatant was removed. For analysis of binding of M-CSF C31S and the M-CSF RGD libraries to c-FMS, yeast cells were incubated with mouse anti-c-myc antibody, 9E10 (Abcam, Cambridge, MA, USA) in a 1:50 ratio and different concentrations of soluble Fc-conjugated human c-FMS (R&D systems, Minneapolis, MN, USA) for 1 h at room temperature. After an additional washing step, cells were labeled with secondary phycoerythrin (PE) anti-mouse (SigmaAldrich, St. Louis, MO, USA), and goat anti-human Fc FITC antibodies (Sigma-Aldrich) for 30 min at 4˚C in the dark. For analysis of binding of M-CSF RGD libraries to integrin, the experiment was performed in integrin binding buffer (IBB; 20 mM Tris, pH 7.5, 2 mM CaCl 2 , 100 mM NaCl, 1 mM MgCl 2 , and 1 mM MnCl 2 ) + 1% BSA. The yeast cells were incubated with chicken anti-c-myc and different concentrations of soluble human α v β 3 integrin (R&D Systems) for 1 h. After an additional washing step, cells were labeled with secondary PE-antichicken and FITC-anti-human β 3 integrin (BioLegend, San Diego, CA, USA) antibodies for 30 min in the dark. Labeled cells were washed with 1 ml PBSA or IBB + 1% BSA. A total of five rounds of affinity maturation sorting were performed; in each sort, a diagonal shape was created with the aim to enrich the high protein binders. In each sort, 0.5% to 2% of the population was collected into a new tube containing SDCC medium. The first sort was performed against 500 nM c-FMS (sort 0), and the subsequent sorts against 500 nM α v β 3 integrin (sort 1), 250 nM α v β 3 integrin (sort 2), 100 nM α v β 3 integrin (sort 3), 20 nM α v β 3 integrin (sort 4), and 50 nM of c-FMS (sort 5). The high-affinity binders were enriched using an iCyt Synergy FACS apparatus (Sony Biotechnology, San Jose, CA, USA).
Choosing and identifying high-affinity α v β 3 integrin and c-FMS binders
To identify the best α v β 3 integrin and c-FMS binders, 25 different clones from sort 4 and 25 different clones from sort 5 were tested for binding to 20 nM α v β 3 integrin, as described in the flow-cytometry-sorting section. Then, 10 α v β 3 integrin binding clones from sort 4 and 10 α v β 3 integrin binding clones from sort 5 having the highest affinities to α v β 3 integrin were analyzed for binding to 50 nM c-FMS. The clones with the highest binding affinity for both α v β 3 integrin and c-FMS were selected, and DNA was extracted from these clones using Zymoprep Yeast Plasmid Miniprep I (Zymo Research, Irvine, CA, USA) according to the manufacturer's protocol. The extracted plasmids were incubated with Escherichia coli-competent cells for 30 min on ice and transferred into 0.2-cm gap cuvettes (Bio-Rad, Hercules, CA, USA). The cuvettes were inserted into a Micropulser electroporator (Bio-Rad) and pulsed with 2.5 kV. Immediately, 1 ml warm Luria Broth (LB) medium was added to each cuvette, and the suspensions were incubated at 37˚C for 1 h. The bacteria were seeded on LB agar plates containing 1:1,000 ampicillin and grown overnight at 37˚C. Colonies were moved to LB medium containing ampicillin and grown overnight. The plasmids were extracted from the bacterial culture with HiYield plasmid mini kit (RBC, Bioscience, Taiwan) according to the manufacturer's protocol. The purified plasmids were sequenced to confirm that they contained the desired sequence and to prevent repetitions (The DNA Microarrays and DNA Sequencing Laboratory, National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev [NIBN, BGU], Beer-Sheva, Israel). To determine the binding specificity to other RGD binding integrins-namely, α v β 5, α 4 β 7 , α 2 β 2b , and α 5 β 1 (BioLegend)-the three chosen M-CSF RGD variants (4.22, 4.24, and 5.6) were analyzed for binding to 250 nM of each integrin. To detect integrin binding, M-CSF RGD variants were incubated with APC anti-human CD49d, APC anti-human CD41, FITC antihuman CD49e, or FITC anti-human CD5 (BioLegend) and analyzed with Accuri C6 flow cytometry analyzer (BD Biosciences, San Jose, CA, USA). M-CSF c-FMS , M-CSF αvβ3 , and M-CSF RGD variants were produced, purified, and characterized as described in S1 Text. The proteins were covalently bound to the chip with 10 mM sodium acetate buffer (pH 4.0) as described above. Then, 1 μM of the M-CSF RGD variant was allowed to flow over the chip at a rate of 50 μl/min for 409 s, followed by 600 s of dissociation with PBS + 1% Tween. The interactions obtained were normalized to the initial protein binding RUs to the chip surface. To achieve statistical significance, we made sure that the χ 2 values were at least 10% or lower than the R max values.
SPR
Computational docking model of α v β 3 integrin, M-CSF RGD , and c-FMS complex
Molecular coordinates for the α v β 3 integrin headpiece were taken from the 1L5G Protein Data Bank (PDB) structure [29] (1-438 of the α v subunit and 55-432 of the β 3 subunit). M-CSF WT in complex with c-FMS was obtained from the 4WRL PDB structure [39] . The M-CSF RGD variant 4.22 was created by replacing residues 25-32 of the native protein with the residues QTSRGDSPS by using PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC (De Lano). The M-CSF RGD structure was energy minimized using the Gromacs 4.6.7 package of programs [41] . Next, M-CSF RGD together with the α v β 3 integrin headpiece were subjected to a receptor-ligand docking procedure by using the PatchDock server [28] . To avoid irrelevant structures, potential binding sites both for the α v β 3 integrin receptor and the M-CSF RGD ligand were defined according to PatchDock recommendations. Slight variations in the interaction restraints yielded five experiments, thus resulting in a total of 500 structures. These were clustered with a 0.5-nm cutoff by using Gromacs. The c-FMS receptor was aligned to the representative models, and snapshots were prepared by the VMD program [42] .
Cell binding assay
M-CSF c-FMS , M-CSF αvβ3 , and two variants of M-CSF RGD (4.22 and 5.6) were labeled with a molar ratio of 1:1 DyLight 488 NHS Ester (Thermo Fisher Scientific) and the purified protein.
The solution was incubated for 1 h at room temperature, and the residual unbound dye was washed three times with Vivaspin (GE Healthcare Life Sciences) with a 3,000-Da cutoff. M-CSF RGD variant 4.24 was not tested for direct cell binding because of low protein-purification yields. The following two assays were conducted:
i. MDA-MB-231 breast cancer cells (ATCC HTB-28) were used for assaying direct cell binding of the purified proteins. Cells were plated at a density of 10 5 per well in 96-well plates and washed with 1 ml 0.1% PBSA. Cells were then centrifuged at 150g for 5 min, and the supernatant was removed; this step was repeated twice. Then, labeled M-CSF c-FMS , M-CSF αvβ3 or M-CSF RGD protein variants were added in IBB + 1% BSA to the cells at different concentrations (1, 2.5, and 7.5 μM) in a total volume of 100 μl and incubated at 4˚C with gentle agitation for 2 h. For the competition assay for variant 5.6, the cells were incubated with 1 μM 5.6 in the presence of 5 μM M-CSF WT or 10 μM cRGD separately or with both together. For determination of c-FMS expression, the cells were stained with PE-anti human CD115 (BioLegend) at a dilution of 1:50, and for α v β 3 integrin expression, with FITC-anti human β 3 integrin (BioLegend) at a dilution of 1:25 for 30 min. Then, the cells were washed twice as described above and analyzed with an Accuri C6 flow cytometry analyzer (BD Biosciences). The mean autofluorescence of the cells was subtracted from the fluorescence reads of all samples. The experiment was repeated three times at each concentration.
ii. Murine BMMs were obtained by killing mice with isoflurane (Piramal, India), followed by flushing the bone marrow from the femurs and tibias of WT C57BL6 mice. The cells were treated with ACK red lysis buffer (Thermo Fisher Scientific) and plated on bacterial culture dishes in αMEM growth medium (Sigma-Aldrich) containing recombinant murine M-CSF (40 ng/ml) (R&D systems). The cells were incubated for 3 d at 37˚C under 5% CO 2 to induce monocyte adhesion and proliferation. The plates were washed with PBS, the cells were detached using a cell scraper, and 10 5 cells were transferred to each well of a 96-well plate. The cells were washed twice with 200 μl 0.1% PBSA. Binding was determined as described for labeled M-CSF RGD proteins. For determination of murine c-FMS expression, anti-mouse CD115 (CSF-1R) (BioLegend) was used at 1:50 concentration and detected with goat anti-rat (PE) antibody (Abcam). For determination of α v β 3 integrin expression, Alexa Fluor 488 anti-mouse/rat CD61 antibody (BioLegend) was used as previously described. Samples were analyzed with an Accuri C6 flow cytometry analyzer (BD Biosciences). The experiment was repeated three times at each concentration.
c-FMS and Akt phosphorylation assay
Murine BMM cells were obtained as described in the previous section. For this assay, 700,000 cells per well were seeded for differentiation with M-CSF (20 ng/ml) and RANKL (20 ng/ml) in a 6-well plate for 48 h held in an incubator at 37˚C. Then, the cells were incubated for 4 h in starvation medium (αMEM growth medium without fetal bovine serum [FBS]) at 37˚C. For the competition assay, cells were washed with PBS, and 1 μM of M-CSF RGD variants and M-CSF c-FMS with M-CSF WT (20 ng/ml) were added to each well for 1 min for c-FMS and 10 min for Akt; the plates were then immediately placed on ice. Cells were lysed with lysis buffer (deoxycholate 0.5%, 25 mM NaF, 10 mM NaPO 4 , 1 mM Na 3 VO 4 ×2H 2 O, 5 mM EDTA, 5 mM EGTA, 100 mM NaCl, 2% Triton X-100, protease inhibitors cocktail, 20 mM para-nitrophenylphosphate [PNPP]) and scraped from the wells, incubated for 10 min on ice, and centrifuged at 14,000 × g at 4˚C for 30 min; the supernatants were then transferred to fresh tubes. To determine whether the variants spontaneously activated c-FMS or Akt, the proteins were added without M-CSF WT , followed by lysis as described. Protein concentrations were determined using a BCA kit (Thermo Fisher Scientific) according to the manufacturer's protocol.
To include and analyze a large sample size, proteins from separate gels were compared using the following method. Fifteen μg of three protein samples were boiled, loaded, and separated on each 10% SDS PAGE for c-FMS and 12% SDS PAGE for Akt (for example, a gel was organized in the following way: protein ladder | 4.22 #1| 4.22 #2 | 4.22 #3 | protein ladder | 4.22 #1 | 4.22 #2 | 4.22 #3, with #1 in both lanes representing the same biological sample, #2 representing the same sample, etc.). Proteins were transferred to a PVDF membrane (Bio-Rad, CA, USA) using a Trans-Blot Turbo Transfer System (Bio-Rad, CA, USA). Membranes were cut into three parts, for example: ladder to 4.22 #3 that was blotted to c-FMS (first 4 samples from left to right above), ladder to 4.22 #3 that was blotted to pc-FMS (phosphorylated form of c-FMS), and low Mw part that was blotted to detect actin. In order to reduce the effects of different exposure times and device errors after blotting that was done with the same antibody stock, all the membranes were imaged at the same day with the same developing system (Fusion FX device manufactured by Vilber Lourmat), the same ECL incubation, and the same exposure times. To make sure that the same amount of protein was loaded and that the ECLdeveloping process was correct, we quantified and normalized each lane to its corresponding actin levels to see that there were no problems with loading or developing (Densitometry values are included in S2 Data). Every sample was normalized to its corresponding actin densitometric value (that was run on the same gel in the same lane) to exclude the effect of different exposure times. For example, 4.22 #1 pc-FMS was normalized to expression levels (4.22 #1 c-FMS) and to its own actin levels (4.22 #1 actin). Membranes were blocked with 5% BSA in TBS (20 mM Tris, 150 mM NaCl, pH 7.6) + 0.1% Tween 20 (TBST) for 1 h. For detection of phosphorylated receptors, a 1:500 ratio of anti-phospho-M-CSF receptor (Tyr723) (Cell Signaling, MA, USA) and a 1:1,000 ratio of anti-phospho-Akt (Ser473) (Cell Signaling) antibodies were added to 5% BSA in TBST for overnight incubation at 4˚C. For total receptor expression, a 1:1,000 ratio of anti-M-CSF receptor (Cell Signaling) and anti-Akt (Cell Signaling) antibodies were added to 5% BSA in TBST for overnight incubation at 4˚C. Membranes were washed three times for 10 min with PBST. Then, the HRP-conjugated anti-rabbit secondary antibody (Cell Signaling) was added at a ratio of 1:1,000 for 1 h, and the membranes were washed again as described. All antibodies were used from the same stock for each blot. The membranes were developed using ECLdeveloping reagent (Biological Industries, Israel) according to the manufacturer's protocol and imaged using a Fusion FX device (Vilber Lourmat, Germany). Each membrane went through the same exposure time, which was according to the antibody that was used. Membranes were stripped with stripping buffer (2% sodium dodecyl sulfate [SDS], 62.5 mM Tris HCl [pH 6.8], 0.8% β-mercaptoethanol) at 50˚C for 30 min, and the procedure was repeated again with actin antibody as a loading control (Cell Signaling). The intensity of the protein bands was measured using ImageJ [43] with the analyze gels tool, and the phosphorylated c-FMS or Akt band intensity was normalized to c-FMS or Akt expression, respectively, and to its corresponding loading control on the same membrane (actin). The experiments with M-CSF c-FMS and M-CSF RGD variants 4.22 and 5.6 were repeated three times, and those with M-CSF RGD variant 4.24 were repeated six times.
Osteoclast actin-belt-formation assay
Murine BMMs were obtained as described in the cell binding assay section. For this assay, 7,000 cells per well were seeded for differentiation with M-CSF (20 ng/ml) and RANKL (20 ng/ml) in a 384 μClear plate (Greiner Bio-One, Austria) for 60 h in an incubator at 37˚C. Then, the different inhibitors were added in a concentration of 5 μM for an additional 24 h. Cells were fixed with a fixation solution (paraformaldehyde 3%, Triton X-100 10%, glutaraldehyde 8%) for 15 min at 37˚C. Following fixation, the cells were washed with PBS and incubated with cytoskeleton buffer (10 mM MES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl 2 , 5 mM glucose, 100 μM sodium borohydride, pH 6.1) for 15 min. To stain for actin, the cells were washed and incubated with Acti-stain 670 phalloidin (Cytoskeleton, CO, USA) for 45 min at room temperature. Thereafter, cells were washed and incubated with DAPI (Thermo Fisher Scientific) for an additional 15 min. Actin rings were visualized by Operetta (Perkin Elmer, MA, USA). Each condition was repeated five times, and from each well, 20 pictures were obtained. For actin belts, quantification osteoclasts were defined as cells harboring three or more nuclei and were counted in a double-blind manner, and actin belts were determined above an intensity threshold by ImageJ software.
Cell viability assay
Mouse mesenchymal stem cells (MSCs) were obtained by flushing the bone marrow from femurs and tibias of 10-weeks-old mice as described in the cell binding assay section. Cells were cultured in MesenCult MSC Basal Medium with 1/5 MSC stimulatory supplements, 50 U/L penicillinstreptomycin, and 10 mg/mL gentamycin and kept in a Hypoxia Incubator Chamber (Thermo Fisher Scientific, Waltham, MA, USA) under 5% oxygen. Then, 7,000 cells were plated in each well of a 96-well plate and held for 48 h in an incubator at 37˚C in the presence of different concentrations of inhibitors (50 nM, 1 μM, and 5 μM). After 48 h, the XTT reagent (Biological Industries, Israel) was added to the cells according to manufacturer's protocol for 2 h at 37˚C. The plate was rocked gently, and the absorbance was measured at 450 nm and 650 nm for background subtraction with a Synergy 2 multidetection microplate reader (Biotek, Winooski, VT, USA). Each condition was repeated three times, and the blank absorbance measurements and the background absorbance were subtracted from the sample's absorbance.
Cell death assay
Murine BMMs were obtained as described in the cell binding assay section, washed with PBS, and detached with a cell scraper, and 1.5 × 10 5 cells were plated in each well of a 24-well plate.
To induce differentiation, M-CSF (20 ng/μl) and RANKL (20 ng/μl) with 1 μM of M-CSF c-FMS, M-CSF αvβ3 , and M-CSF RGD variants and GW2580 (Abcam, Cambridge, MA, USA) were added for 48 h. Then, cells were detached with Accutase (Biological industries, Israel), centrifuged at 300 × g for 5 min, and washed three times with PBSA 0.1%. PI was added, and cells were analyzed with Accuri C6 flow cytometry analyzer.
Cell differentiation assay
Murine BMMs were obtained as described in the cell-binding-assay section, washed with PBS, and detached with a cell scraper, and 2 × 10 4 cells were plated in each well of a 96-well plate.
Human peripheral blood CD14 + monocytes (PromoCell, Germany) were grown in complete . After 72-96 h, once the cells had differentiated fully, they were fixed in 4% paraformaldehyde and stained using a TRAP staining kit (Sigma-Aldrich, USA) according to the manufacturer's protocol with additional staining of the nuclei with DAPI. As a positive control, PBS was used instead of the inhibitors, and negative controls comprised cells incubated in differentiation medium without RANKL and inhibitors. Osteoclast parameters were obtained by analysis of 20 images from random areas in each well; the osteoclasts were observed with an Olympus ×83 microscope with an automated stage. For murine osteoclasts differentiation, a total of 2,340 frames were analyzed for 1,581 osteoclasts and 5,313 nuclei; for human CD14 + , a total of 1,620 frames were analyzed for 477 osteoclasts and 1,897 nuclei. Osteoclasts were defined as TRAP-positive cells harboring three or more nuclei and were counted in a double-blind manner, and the number of nuclei in the osteoclasts and the total osteoclast surface area were determined using ImageJ software. To evaluate the TRAP staining in each well, the plate was measured with a 650 nm Synergy 2 multidetection microplate reader. Three repeats were performed for every condition, and each repeat was normalized to the positive control values.
qPCR
Murine BMMs were obtained as described in the cell binding assay section, washed with PBS, and detached with a cell scraper, and 7.5 × 10 5 cells were plated in each well of a 6-well plate.
Then, osteoclast differentiation was induced as described in the cell differentiation assay section with and without inhibitors at a concentration of 50 nM. When cells reached full differentiation, they were washed once with PBS and lysed, and the mRNA was isolated using TRIzol reagent (Thermo Fisher Scientific). cDNA was prepared using a cDNA Reverse Transcriptase kit (Applied Biosystems) according to manufacturer's protocol. For each reaction, 100 ng of cDNA was used with a SYBR Green gene expression assay (Applied Biosystems) and analyzed with a LightCycler 480 II analyzer (Roche) for OSCAR (forward primer: CACCTACTGTTGCTATT ACC, reverse primer: GAACCTTCGAAACTGATGAC) and NFATc1 (forward primer: CCAG TTCTACTTGGATGATG, reverse primer: GTAAGTTGGGATTTCTGAGTG). Expression levels of genes were normalized to the HPRT (forward primer: CCCCAAAATGGTTAAGG TTG, reverse primer: AGTACTCATTATAGTCAAGGGC) reference gene using the comparative Ct method (ΔΔ Ct) that was compared to the positive control.
In vivo imaging
M-CSF RGD variant 5.6 was labeled with DyLight 680-NHS Ester and was washed rigorously to remove residual dye molecules. Unconjugated dye was incubated with Tris for 30 min at room temperature. C57BL6 mice were anesthetized in an isoflurane chamber and injected s.c. with 2 nmol of labeled protein or unconjugated dye. Then, the mice were killed with isoflurane, and their internal organs were removed and placed on the IVIS platform and imaged with the IVIS system (Perkin Elmer, MA, USA). Similarly, 3 h after injection, C57BL6 mice were killed, and their bones were placed on the IVIS platform and photographed.
Injection of ovariectomized mice with M-CSF RGD
Ten-weeks-old female C57BL6 mice were ovariectomized under complete anesthesia. Two weeks after the operation, the mice were injected s.c. twice a day for 3 d with PBS or 10 mg/kg of M-CSF RGD variants 4.22 or 5.6. Three h after the last injection, the mice were anesthetized with isoflurane, and their blood was collected through a cardiac puncture. Then, blood samples were centrifuged at 4,000 × g for 10 min, and the serum samples were transferred to fresh tubes. To determine the serum CTX-I levels, a RatLaps ELISA (Immunodiagnostic systems, UK) was used according to manufacturer's protocol. Hemolytic samples were not used.
Statistical analysis
The data from the differentiation assay was analyzed for column statistics with GraphPad Prism version 5.00 for Windows (La Jolla, CA, USA). Data is shown as means ± SEM. Statistical significance was determined by column statistics and ANOVA test analysis. A p value < 0.05 was considered statistically significant. 
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